Mounjaro is the FDA-approved brand product dispensed by retail pharmacies, while compounded tirzepatide is prepared by 503A compounding pharmacies for individual patients
Future strategies likely will use combination therapy akin to bundle protocols
You use the vial within or close to the 28-day window, waste is minimal, and the cost per milligram is typically lower for the larger vial size
Serious risks include: Thyroid tumors (including cancer) Gastroparesis (stomach paralysis) Pancreatitis Gallbladder issues Hypoglycemia (especially with type 2 diabetes) Kidney failure Serious allergic reactions Vision changes Increased heart rate Depression or suicidal thoughts Common side effects: nausea, diarrhea, vomiting, constipation, stomach pain, headache, tiredness, indigestion, bloating, belching, heartburn, and upper respiratory symptoms